K V PHARMA CL A (GREY:KVPHQ)

Monday, September 16, 2013 | Web News
ST. LOUIS, Sept. 16, 2013 /PRNewswire/ -- K-V Pharmaceutical Company ("KV") today announced that its plan of...
Monday, July 29, 2013 | Web News
In our 7/17/2013 email we discussed that after further due diligence, prompted by a correspondence with one of our premium members, we now know why some...
Friday, July 26, 2013 | Web News
Email Alert Chain Alert Sent to Members on 7/15/2013 K-V Pharmaceuticals (OOTC:KVPHQ) ($0.66) - The Q denotes...
See All Research...
K-V Pharmaceutical Company operates as a specialty branded pharmaceutical marketing company primarily focusing on women’s health care in the United States. It provides Evamist, a transdermal estrogen therapy, which delivers a low dose of estradiol for the treatment of moderate-to-severe vasomotor symptoms due to menopause; and Makena, a hydroxyprogesterone caproate injection, which reduces the risk of preterm birth in women with a singleton pregnancy, who have a history of singleton spontaneous preterm birth. The company markets its products directly to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, and group purchasing organizations; and indirectly to independent pharmacies, managed care organizations, hospitals, pharmacy benefit management companies, and government entities principally through wholesaler or distributor customers. K-V Pharmaceutical Company was founded in 1942 and is headquartered in St. Louis, Missouri. On August 4, 2012, K-V Pharmaceutical Company filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of New York, Manhattan. It is in joint administration with K-V Discovery Solutions, Inc.

Web site: http://www.kvpharmaceutical.com

Last updated February 1, 2013